Xspray Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-149.12	-156.91	-287.04	-181.73	-133.07	-97.95
Depreciation & Amortization	5.55	5.58	8.55	9.19	9.53	8.87
Other Adjustments	-12.01	-11.41	51.54	0.85	16.94	33.1
Change in Receivables	0.45	-0.4	1.34	-4.11	-2.94	-5.71
Changes in Inventories	7.08	-1.96	-6.03	-35.23	-	-
Changes in Accounts Payable	-9.46	-28.07	9.28	7.76	-0.63	10.09
Operating Cash Flow	-157.51	-193.16	-222.37	-203.28	-110.18	-51.61
Capital Expenditures	-	-	-4.38	-2.69	-24.47	-1.31
Purchases of Intangible Assets	-15.55	-29.19	-37.76	-49.86	-103.82	-94.65
Other Investing Activities	-	-	-	-13.33	-7.06	-9.85
Investing Cash Flow	-15.55	-29.19	-42.14	-65.88	-135.35	-105.82
Long-Term Debt Issued	120	120	96	45	-	-
Long-Term Debt Repaid	-5.21	-105.14	-4.89	-1.65	-2.13	-2.15
Net Long-Term Debt Issued (Repaid)	114.79	14.86	91.11	43.35	-2.13	-2.15
Issuance of Common Stock	161.13	161.13	235.4	297.92	100	99.88
Net Common Stock Issued (Repurchased)	161.13	161.13	235.4	297.92	100	99.88
Other Financing Activities	-7.62	-7.7	-20.4	-25.68	-4.06	5.99
Financing Cash Flow	168.31	168.29	306.11	315.59	93.81	103.71
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.25	-0.44	0.33	-0.31	-	-
Net Cash Flow	-4.76	-54.06	41.6	46.44	-151.72	-53.72
Free Cash Flow	-157.51	-193.16	-226.75	-205.97	-134.65	-52.92
FCF Margin	-3108.57%	-3003.16%	-10818.10%	-648.37%	-6176.38%	-8067.07%
Free Cash Flow Per Share	-3.98	-5.02	-6.84	-7.74	-6.39	-2.75
Levered Free Cash Flow	-46.56	-181.04	-187	-157.29	-149.36	-81.21
Unlevered Free Cash Flow	-146.03	-181.45	-279.77	-202.72	-148.64	-80.31